Posted On: 03/03/2015 8:49:58 AM
Post# of 89360
$IGXT (2) Two more drugs to be filed this year, PAR VersaFilm, DAVA VersaTab
IntelGenx will have (4) drug products in FDA review this year with (2) two
of them nearing the end of there cycles and hopefully adding to the revenue
stream in the near future.
Partner PAR Pharma VersaFilm Suboxone
Partner Redhill VersaFilm RIZAPORT
Partner Dava VersaTab Hypertension
Partner PAR VersaFilm (undisclosed)
RIZAPORT Europe decision in Q2, 2015
Behind these FDA filed products IntelGenx
currently has (5) other drug development products
active in there pilot studies. (3) three of the drugs
are partnered and (2) two of the drugs un-partnered.
And of course, we all know the status of our Forfivo XL
product. Q4 April, 2015
http://www.intelgenx.com/investors/presentations.html
IntelGenx will have (4) drug products in FDA review this year with (2) two
of them nearing the end of there cycles and hopefully adding to the revenue
stream in the near future.
Partner PAR Pharma VersaFilm Suboxone
Partner Redhill VersaFilm RIZAPORT
Partner Dava VersaTab Hypertension
Partner PAR VersaFilm (undisclosed)
RIZAPORT Europe decision in Q2, 2015
Behind these FDA filed products IntelGenx
currently has (5) other drug development products
active in there pilot studies. (3) three of the drugs
are partnered and (2) two of the drugs un-partnered.
And of course, we all know the status of our Forfivo XL
product. Q4 April, 2015
http://www.intelgenx.com/investors/presentations.html
(0)
(0)
